CircRNAs as upstream regulators of miRNA//HMGA2 axis in human cancer

IF 12 1区医学 Q1 PHARMACOLOGY & PHARMACY

Pharmacology & Therapeutics Pub Date : 2024-08-31 DOI:10.1016/j.pharmthera.2024.108711

Qiqi Sun , Xiaoyong Lei , Xiaoyan Yang

{"title":"CircRNAs as upstream regulators of miRNA//HMGA2 axis in human cancer","authors":"Qiqi Sun , Xiaoyong Lei , Xiaoyan Yang","doi":"10.1016/j.pharmthera.2024.108711","DOIUrl":null,"url":null,"abstract":"<div><div>High mobility group protein A2 (HMGA2) is widely recognized as a chromatin-binding protein, whose overexpression is observed in nearly all human cancers. It exerts its oncogenic effects by influencing various cellular processes such as the epithelial-mesenchymal transition, cell differentiation, and DNA damage repair. MicroRNA (miRNA) serves as a pivotal gene expression regulator, concurrently modulating multiple genes implicated in cancer progression, including HMGA2. It also serves as a significant biomarker for cancer. Circular RNA (circRNA) plays a crucial role in gene regulation primarily by sequestering miRNAs and impeding their ability to enhance the expression of other genes, including HMGA2. Increasingly, studies have underscored the vital role of miRNA/HMGA2 interactions in cancer. Given the significance of circRNA as an upstream regulatory mediator and the complexity of regulatory mechanisms, we hereby present a comprehensive overview of the pivotal role of circRNAs as upstream regulators of the miRNA//HMGA2 axis in human cancers. This insight may herald a novel direction for future cancer research.</div></div>","PeriodicalId":402,"journal":{"name":"Pharmacology & Therapeutics","volume":"263 ","pages":"Article 108711"},"PeriodicalIF":12.0000,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0163725824001311","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

High mobility group protein A2 (HMGA2) is widely recognized as a chromatin-binding protein, whose overexpression is observed in nearly all human cancers. It exerts its oncogenic effects by influencing various cellular processes such as the epithelial-mesenchymal transition, cell differentiation, and DNA damage repair. MicroRNA (miRNA) serves as a pivotal gene expression regulator, concurrently modulating multiple genes implicated in cancer progression, including HMGA2. It also serves as a significant biomarker for cancer. Circular RNA (circRNA) plays a crucial role in gene regulation primarily by sequestering miRNAs and impeding their ability to enhance the expression of other genes, including HMGA2. Increasingly, studies have underscored the vital role of miRNA/HMGA2 interactions in cancer. Given the significance of circRNA as an upstream regulatory mediator and the complexity of regulatory mechanisms, we hereby present a comprehensive overview of the pivotal role of circRNAs as upstream regulators of the miRNA//HMGA2 axis in human cancers. This insight may herald a novel direction for future cancer research.

查看原文本刊更多论文

CircRNA 是人类癌症中 miRNA//HMGA2 轴的上游调节因子。

高迁移率基团蛋白 A2（HMGA2）被广泛认为是一种染色质结合蛋白，几乎所有人类癌症中都能观察到它的过表达。它通过影响上皮-间质转化、细胞分化和 DNA 损伤修复等各种细胞过程来发挥致癌作用。微小核糖核酸（miRNA）是一种关键的基因表达调节因子，可同时调节与癌症进展有关的多个基因，包括 HMGA2。它还是癌症的重要生物标志物。环状 RNA（circRNA）在基因调控中起着至关重要的作用，主要是通过封闭 miRNA，阻碍其增强包括 HMGA2 在内的其他基因的表达。越来越多的研究强调了 miRNA/HMGA2 相互作用在癌症中的重要作用。鉴于 circRNA 作为上游调控介质的重要性和调控机制的复杂性，我们在此全面概述了 circRNA 作为 miRNA//HMGA2 轴上游调控因子在人类癌症中的关键作用。这一见解可能预示着未来癌症研究的新方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacology & Therapeutics 医学-药学

CiteScore

23.00

自引率

0.70%

发文量

222

审稿时长

90 days

期刊介绍： Pharmacology & Therapeutics, in its 20th year, delivers lucid, critical, and authoritative reviews on current pharmacological topics.Articles, commissioned by the editor, follow specific author instructions.This journal maintains its scientific excellence and ranks among the top 10 most cited journals in pharmacology.